Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2–Metastatic Breast Cancer

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy are a preferred treatment option for premenopausal and postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (mBC). Palboc...

Descripción completa

Detalles Bibliográficos
Autores principales: Podsada, Kimberly, Ryan, Joanne C., Orbaugh, Kristi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646629/
https://www.ncbi.nlm.nih.gov/pubmed/33575067
http://dx.doi.org/10.6004/jadpro.2020.11.7.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646629/
https://www.ncbi.nlm.nih.gov/pubmed/33575067
http://dx.doi.org/10.6004/jadpro.2020.11.7.5

Ejemplares similares